Andrew D'Silva

Nano-cap pharma company Alimera Sciences Inc (NASDAQ: ALIM) could nearly triple in value for three key reasons, according to B. Riley FBR.  The Analyst Analyst Andrew D'Silva initiated coverage of Alimera Sciences with a Buy rating and $2.75 price target. The Thesis Alimera is a...